Nutra Pharma CORP 10-Q quarterly reports

Nutra Pharma Corp. reports a net loss of $459,675 for Q1 2026, citing ongoing liquidity challenges and significant debt defaults.

Nutra Pharma Corp. reported a wider net loss for the third quarter and first nine months of 2025, driven by increased operating expenses and fluctuations in derivative liabilities, despite a rise in net sales to unrelated customers.

Nutra Pharma Corp. reported a net income of $369,577 for Q2 2025, driven by non-operating gains, despite ongoing substantial doubt about its ability to continue as a going concern due to significant accumulated deficits and debt defaults.

Nutra Pharma Corp. reported a widened net loss for Q2 2024 and a significant accumulated deficit, raising substantial doubt about its ability to continue as a going concern.

Nutra Pharma Corp. reported a significant net loss and declining revenues for Q1 2024, raising substantial doubt about its ability to continue as a going concern.

Nutra Pharma Corp. reported a significant net loss for the nine months ended September 30, 2023, alongside substantial debt and ongoing legal challenges, raising going concern doubts.

Nutra Pharma Corp. reported a significant net loss for Q2 2023, driven by derivative fair value changes and ongoing liquidity concerns, despite increased product sales.

Nutra Pharma Corp. reported increased sales in Q1 2023 but faced a significant net loss, substantial debt defaults, and ongoing going concern doubts, despite settling major lawsuits post-period.